These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28007630)

  • 21. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Nabeshima K
    Histopathology; 2017 Dec; 71(6):1011-1014. PubMed ID: 28746778
    [No Abstract]   [Full Text] [Related]  

  • 22. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
    Pu RT; Pang Y; Michael CW
    Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinctive clinical characteristics of malignant mesothelioma in young patients.
    Thomas A; Chen Y; Yu T; Gill A; Prasad V
    Oncotarget; 2015 Jun; 6(18):16766-73. PubMed ID: 26202904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
    Multidisciplinary Committee of Oncology, Chinese Physicians Association
    Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
    Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
    Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleural neoplastic pathology.
    Karpathiou G; Stefanou D; Froudarakis ME
    Respir Med; 2015 Aug; 109(8):931-43. PubMed ID: 26048082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
    Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
    Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of second primary cancers after malignant mesothelioma and vice versa.
    Chen T; Kharazmi E; Lou J; Zhang X; Sundquist K; Hemminki K
    Cancer Lett; 2016 Aug; 379(1):94-9. PubMed ID: 27260871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
    Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
    Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Peritoneal tumor pathology - case no 4: an aggressive peritoneal tumor].
    Sabourin JC
    Ann Pathol; 2015 Aug; 35(4):338-41. PubMed ID: 26189364
    [No Abstract]   [Full Text] [Related]  

  • 38. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
    Husain AN; Colby TV; Ordóñez NG; Krausz T; Borczuk A; Cagle PT; Chirieac LR; Churg A; Galateau-Salle F; Gibbs AR; Gown AM; Hammar SP; Litzky LA; Roggli VL; Travis WD; Wick MR
    Arch Pathol Lab Med; 2009 Aug; 133(8):1317-31. PubMed ID: 19653732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
    Husain AN; Colby T; Ordonez N; Krausz T; Attanoos R; Beasley MB; Borczuk AC; Butnor K; Cagle PT; Chirieac LR; Churg A; Dacic S; Fraire A; Galateau-Salle F; Gibbs A; Gown A; Hammar S; Litzky L; Marchevsky AM; Nicholson AG; Roggli V; Travis WD; Wick M;
    Arch Pathol Lab Med; 2013 May; 137(5):647-67. PubMed ID: 22929121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.